Form D · Biotechnology

Embold Therapeutics, Inc.

Redwood City, CA · CIK 0002109643

Offering snapshot reported Jul 24, 2026 · SEC filing

Reported sold
$2.47M
Offering amount: $4.98M
Investors reported
7
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jan 21, 2026
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$1.24M$2.47MFeb 9, 2026: $130,000.00Feb 9, 2026Jul 24, 2026: $2,470,587.00Jul 24, 2026

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$130,000 → $2,470,587
  • Reported investors2 → 7

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jul 24, 2026Amendment$2,470,587$2,340,587vs Feb 9, 20267SEC filing
Feb 9, 2026Initial$130,000No comparison2SEC filing
Feb 9, 2026Initial$500,000No comparison1SEC filing

Offering details

Securities
Option to acquire, Security to be acquired
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-572899

Source: Form D, filed Jul 24, 2026. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Gjalt W. Huisman Director, Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
2682 Eaton Ave
Redwood City, CA, 94062
Phone: (650) 200-7297